Premacure, Shire deal

Shire acquired rare eye disease company Premacure for an undisclosed upfront payment, plus undisclosed milestones. Premacure's Premiplex (formerly iPlex) is in Phase II testing to prevent retinopathy of prematurity (ROP), a rare disease that primarily affects premature infants and can lead to blindness. The protein replacement therapy is a complex of insulin-like growth factor-1 ( IGF-1) and its principal binding protein, IGF binding protein 3 ( IGFBP3). ...